Literature DB >> 32686825

Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.

Matthew A Spinelli1, Brentton Lowery2, Jennifer A Shuford3, Jon Spindler4, Mary F Kearney4, Jenny R McFarlane3, Cheryl McDonald5, Hideaki Okochi1, Nhi Phung1, Karen Kuncze1, Kathryn Jee6, DeeJay Johannessen2, Peter L Anderson7, Dawn K Smith8, Patricia Defechereux6, Robert M Grant6, Monica Gandhi1.   

Abstract

Cases of seroconversion on pre-exposure prophylaxis (PrEP) should be carefully investigated, given their public health implications and rarity. We report a case of transmitted drug resistance causing seroconversion on PrEP in spite of high adherence, confirmed with dried blood spot and segmental hair drug-level testing and single-genome sequencing.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV seroconversion; PrEP; PrEP failure; adherence; single-genome-sequencing

Mesh：

Substances：

Year:  2021        PMID： 32686825      PMCID： PMC8315126          DOI： 10.1093/cid/ciaa1011

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  11 in total

1.  Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.

Authors:  Mian-Er Cong; Ae S Youngpairoj; Qi Zheng; Wutyi Aung; James Mitchell; Elizabeth Sweeney; Debra L Hanson; R Michael Hendry; Charles Dobard; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.

Authors:  Stephanie E Cohen; Darpun Sachdev; Sulggi A Lee; Susan Scheer; Oliver Bacon; Miao-Jung Chen; Hideaki Okochi; Peter L Anderson; Mary F Kearney; Susa Coffey; Hyman Scott; Robert M Grant; Diane Havlir; Monica Gandhi
Journal:  Lancet HIV       Date:  2018-11-29       Impact factor: 12.767

3.  Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Authors:  Elske Hoornenborg; Maria Prins; Roel C A Achterbergh; Lycke R Woittiez; Marion Cornelissen; Suzanne Jurriaans; Neeltje A Kootstra; Peter L Anderson; Peter Reiss; Henry J C de Vries; Jan M Prins; Godelieve J de Bree
Journal:  Lancet HIV       Date:  2017-09-14       Impact factor: 12.767

4.  Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.

Authors:  Julia L Marcus; Leo B Hurley; Charles Bradley Hare; Dong Phuong Nguyen; Tony Phengrasamy; Michael J Silverberg; Juliet E Stoltey; Jonathan E Volk
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-15       Impact factor: 3.731

5.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

6.  Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.

Authors:  Joshua T Thaden; Monica Gandhi; Hideaki Okochi; Christopher B Hurt; Mehri S McKellar
Journal:  AIDS       Date:  2018-06-01       Impact factor: 4.177

7.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

8.  Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Authors:  Martin Markowitz; Howard Grossman; Peter L Anderson; Robert Grant; Monica Gandhi; Howard Horng; Hiroshi Mohri
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

9.  Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.

Authors:  Donn J Colby; Eugene Kroon; Carlo Sacdalan; Monica Gandhi; Robert M Grant; Praphan Phanuphak; Jintanat Ananworanich; Merlin L Robb; Nittaya Phanuphak
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

10.  HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

Authors:  Teri Liegler; Mohamed Abdel-Mohsen; L Gordon Bentley; Robert Atchison; Timothy Schmidt; Jacqueline Javier; Megha Mehrotra; Christopher Eden; David V Glidden; Vanessa McMahan; Peter L Anderson; Peilin Li; Joseph K Wong; Susan Buchbinder; Juan V Guanira; Robert M Grant
Journal:  J Infect Dis       Date:  2014-04-16       Impact factor: 5.226
View more
  4 in total

Review 1.  How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?

Authors:  Urvi M Parikh; John W Mellors
Journal:  Curr Opin HIV AIDS       Date:  2022-07-01       Impact factor: 4.061

2.  Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.

Authors:  Susan P Buchbinder; Aaron J Siegler; Kenneth Coleman; Eric Vittinghoff; Gretchen Wilde; Annie Lockard; Hyman Scott; Peter L Anderson; Nicole Laborde; Ariane van der Straten; Richard H Christie; Michelle Marlborough; Albert Y Liu
Journal:  AIDS Behav       Date:  2022-08-19

3.  Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project.

Authors:  Lisa Levy; Jill M Peterson; Lauren D Kudrick; Bhavna Chohan; Everline Bosek; Irene Mukui; Mary Mugambi; Sarah Masyuko; Owen Mugurungi; Nonhlanhla Ndlovu; Imelda Mahaka; Megan Dunbar; Anita Hettema; Rudo A P Kuwengwa; Sindy Matse; Saiqa Mullick; Letitia Greener; Cara O'Connor; Diantha Pillay; Maria Fawzy; John W Mellors; Urvi M Parikh
Journal:  Glob Health Sci Pract       Date:  2022-04-29

4.  HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.

Authors:  Catherine A Koss; Diane V Havlir; James Ayieko; Dalsone Kwarisiima; Jane Kabami; Gabriel Chamie; Mucunguzi Atukunda; Yusuf Mwinike; Florence Mwangwa; Asiphas Owaraganise; James Peng; Winter Olilo; Katherine Snyman; Benard Awuonda; Tamara D Clark; Douglas Black; Joshua Nugent; Lillian B Brown; Carina Marquez; Hideaki Okochi; Kevin Zhang; Carol S Camlin; Vivek Jain; Monica Gandhi; Craig R Cohen; Elizabeth A Bukusi; Edwin D Charlebois; Maya L Petersen; Moses R Kamya; Laura B Balzer
Journal:  PLoS Med       Date:  2021-02-09       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.